Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2021-05-26 Interim / Quarterly Rep…
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT' and covers the period 'January - March 2021'. It contains detailed financial data (net sales, operating loss, cash equivalents) and substantive management analysis of business operations, clinical trials, and future outlook. It is not a short announcement or a certification, but a comprehensive quarterly financial report. Q1 2021
2021-05-26 English
Cantargia rapporterar positiva resultat från en pågående fas IIa klinisk studie i bukspottkörtelcancer med nadunolimab och cellgifter
Earnings Release Classification · 99% confidence The document is a 'Pressmeddelande' (Press Release) dated May 19, 2021, announcing positive results from an ongoing Phase IIa clinical study (CANFOUR) regarding the drug nadunolimab for pancreatic cancer. It details efficacy data (PFS, overall survival), safety profile, and future plans, including an upcoming presentation of the results. This content structure—a formal announcement of clinical trial results and business updates, often released under market abuse regulations (as indicated by the final paragraph: 'EU:s marknadsmissbruksförordning')—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of periodic financial/operational results (clinical trial data update), it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical results, even if the period is a clinical trial update rather than a fiscal quarter. It is not a full Annual Report (10-K), a transcript (CT), or a dedicated management discussion (MDA). Given the nature of reporting clinical trial outcomes which drive investor interest, ER is the most appropriate fit over the general RNS fallback. FY 2021
2021-05-19 Swedish
Cantargia reports positive results in ongoing phase IIa clinical trial in pancreatic cancer using nadunolimab and chemotherapy
Earnings Release Classification · 95% confidence The document is a press release dated May 19, 2021, announcing positive efficacy results from an ongoing Phase IIa clinical trial (CANFOUR) for Cantargia's drug nadunolimab in pancreatic cancer. It details clinical outcomes (iPFS, survival, response rates, side effects) and mentions future steps, including presenting the results at an R&D day. This content is characteristic of an initial announcement of periodic financial/clinical performance highlights, rather than a comprehensive annual report (10-K), a full audit report (AR), or a detailed management discussion (MDA). It fits best under the 'Earnings Release' (ER) category, as it is the primary release of period-specific performance data, even though the performance here is clinical trial efficacy rather than revenue/profit. It is not a general regulatory filing (RNS) because it is a specific type of announcement (clinical trial results press release). FY 2021
2021-05-19 English
Cantargia presents new preclinical data showing unique improvement of heart function in myocarditis using antibody CAN10
Earnings Release Classification · 99% confidence The document is a press release dated May 10, 2021, announcing new preclinical data on the antibody CAN10 presented at the American Association of Immunologists annual meeting. It details scientific findings, mentions ongoing clinical development (CAN04 in Phase IIa), and provides company background. This format—a news announcement summarizing recent scientific/business developments, often referencing a presentation or publication—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management discussion (MDA), and it is announcing results rather than just announcing the publication of a report (RPA), it fits best as an Earnings Release (ER) if the data release is tied to a reporting period, or RNS if it's purely scientific news. Given the context of presenting data at a major meeting, it functions as an update on R&D progress, which often accompanies or substitutes for a formal earnings update in biotech/pharma. However, since it is a general press release announcing scientific progress and not explicitly stating quarterly/periodical financial results (though it mentions CAN04's Phase IIa status), the most appropriate general category for a non-standard, material announcement is Regulatory Filing (RNS). If the document were focused purely on financial performance highlights, ER would be better. Since it's a scientific/pipeline update released via press release, RNS is the safest fit as a material, non-standard disclosure. FY 2021
2021-05-10 English
Cantargia presenterar nya prekliniska data som visar att antikroppen CAN10 åstadkommer en unik förbättring av hjärtfunktion vid hjärtmuskelinflammation
Earnings Release Classification · 99% confidence The document is a press release ("Pressmeddelande") from Cantargia AB dated May 10, 2021. It announces the presentation of new preclinical data regarding their antibody CAN10 at a scientific meeting (AAI Virtual IMMUNOLOGY 2021). The text details scientific findings, mentions ongoing clinical trials for other products (CAN04), and concludes with standard company boilerplate and a statement about compliance with the EU Market Abuse Regulation. This type of announcement, focusing on scientific updates, data presentation, or general corporate news that isn't a formal financial report (like 10-K, IR, or ER), typically falls under general regulatory announcements or investor relations material. Since it is a press release announcing scientific progress rather than a formal financial filing, and it doesn't fit specific categories like DIV, DIRS, or MANG, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the presentation itself. Given it is a press release *about* a presentation, RNS is the most appropriate general category for non-standard regulatory disclosures. FY 2021
2021-05-10 Swedish
Cantargia tar nästa steg i utvecklingen av antikroppen CAN04 med en ny klinisk studie i trippelnegativ bröstcancer
Legal Proceedings Report Classification · 99% confidence The document is a press release ("Pressmeddelande") dated May 6, 2021, announcing a new clinical study involving the drug candidate CAN04 for triple-negative breast cancer, signed via a letter of intent with GEICAM. It details clinical trial plans, scientific rationale, and quotes from management. The final paragraph explicitly states: "Denna information är sådan som Cantargia AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." (This information is such that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation). This structure—a formal announcement of material, non-public information required by market regulations, often concerning strategic developments like clinical trials—is characteristic of a general regulatory announcement or a press release that serves as a primary disclosure mechanism. Since it is not a full financial report (10-K, IR), a specific financial event (CAP, DIV), or a transcript (CT), the most appropriate general category for a mandatory regulatory disclosure that doesn't fit a more specific operational code is Regulatory Filings (RNS). It is not an Earnings Release (ER) as it focuses on clinical development, not period results.
2021-05-06 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.